רווחיות מכירות לפי רווח נקי Nautilus Bio (NAUT)

Nautilus Biotechnology (NAUT) is developing an advanced proteome study system for the synthesis of modern pharmaceuticals. The historical sales margin level displayed by the GURU.Markets portal confirms this strategy, with the current level sitting around -13816.80. Business efficiency is based on proprietary chips for low-cost DNA screening and modernized optical systems in laboratories.
Nautilus Bio (NAUT) - פילוחי מדדים ודוחות פיננסיים

Sales margin determines the share of net profit in every dollar of revenue, measuring the efficiency of converting income into final capital. The current value of -13816.80 reflects the ability of Nautilus Biotechnology (NAUT) to retain profit amidst fierce competition with DNA sequencing behemoths. By analyzing the company's sales margin history, an investor can discern the real cost of implementing proteomic tools in laboratories. A compression of this metric signals a loss of competitive advantage, while the stability of the metric confirms the resilience of the business model.